X0306 4 2021-07-22 0 0001818331 Sema4 Holdings Corp. SMFR 0001873901 Prentice Anthony C/O SEMA4 HOLDINGS CORP. 333 LUDLOW ST, NORTH TOWER, 8TH FL. STAMFORD CT 06902 0 1 0 0 Chief Product Officer Employee Stock Option (Right to Buy) 0.1529 2021-07-22 4 A 0 1733674 A 2027-09-30 Class A Common Stock 1733674 1733674 D Employee Stock Option (Right to Buy) 0.7659 2021-07-22 4 A 0 449871 A 2030-02-17 Class A Common Stock 449871 449871 D Employee Stock Option (Right to Buy) 0.7659 2021-07-22 4 A 0 196666 A 2030-02-17 Class A Common Stock 196666 196666 D 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards. The merger agreement provides that certain former stockholders and equity award holders of Sema4 will receive additional shares of the Issuer's Class A common stock and awards of restricted stock units upon the achievement of certain vesting conditions. /s/ Daniel Clark, Attorney-in-Fact 2021-07-26